期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 24, 期 4, 页码 319-333出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2013.01.005
关键词
Immunogenic cell death; ICD inducers; Cancer; Tumour immunology; Anti-tumour immunity
资金
- KU Leuven [GOA/11/009]
- Federal Research Programme [IAP 6/18]
- FWO-Vlaanderen [G.0661.09, G.0728.10, G.0584.12N, G.0728.10 31507110, 3G067512, G060713N, G0A5413N]
- BOF Postdoctoral Mandate (PDM) from KU Leuven [PDMK/12/146]
Recently, cytokine-based pro-tumourigenic signalling has been found to play a major role in the immune system's pro-tumourigenic activity. On the other hand, other recent findings have shown that immunogenic cancer cell death triggered by certain anticancer modalities might reset the dysfunctional immune system towards the activation of a long-lasting protective anti-tumour response. Therefore, using inducers of immunogenic cell death (ICD) that can prevent or impede tumour-promoting cytokine signalling is one of the best ways of instigating or restoring efficient anti-tumour immunity. In this review it is discussed, how the different ICD inducers interact with the immune system and influence cytokine-based pro-tumourigenic signalling. We believe that it is crucial to discover or develop new anticancer therapeutic modalities that can induce ICD and impede tumour-promoting cytokine signalling. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据